STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Today Diamyd Medical (Pink Sheets:DMYDY)(STO:DIAMB) reported that a team of Nordic researchers has applied for permission to begin a study using the Diamyd® diabetes vaccine to vaccinate people at risk of developing type 1 diabetes.
